Introduction: Conventional cerebral angiography is a commonly performed procedure in medicine. Vascular closure devices have been developed as alternatives to manual compression at the arteriotomy site and prolonged bed rest. The risks of using these devices include arterial dissection, groin hematoma, and device failure. Herein, we describe our experience with the use of a novel device used for arterial access and closure, the AXERA 2 Access System. Methods: A total of 13 patients underwent vascular access and closure with the AXERA 2 Access System. Results: Arterial access using the AXERA 2 Access System was achieved in 11 of 13 patients. Amongst the patients with successful access, one patient experienced a groin hematoma requiring manual compression and two patients suffered occlusions of the common femoral artery due to dissections, with both patients requiring femoral artery thromboendarterectomies.
Introduction
Percutaneous puncture of the femoral artery is the first step in performing the vast majority of diagnostic and interventional neuroendovascular procedures. Subsequent vascular access-site management is crucial to safe, efficient, and comfortable procedural completion. A number of vascular closure devices (VCDs) have been recently developed as alternatives to manual compression and extended bed rest for arteriotomy closure. Initial studies posited VCD use as a means to increase closure efficacy, decrease time to ambulation and discharge, facilitate patient throughput, and reduce overall cost. 1, 2 Moreover, VCDmediated arteriotomy closure has been shown to increase patient comfort, with patients reporting less pain than those managed with manual compression alone. 2 While VCD utilization has increased, widespread adoption has been tempered by operator learning curve, device costs, impaired or delayed ability to reaccess the femoral artery after deployment, and potential for complication development. 3À6 An increased frequency of access-site complications inclusive of groin hematomas, 7À12 iatrogenic pseuodaneurysm formation, 11 and retroperitoneal hemorrhage 13À17 has been noted. Other significant vascular complications relate to the formation of traumatic dissections at the access site with consequent vessel stenosis and limb ischemia 13,18À22 as well as intra-arterial sealant deployment, 23 with the potential for local thrombosis and vessel occlusion. 20 The recently introduced AXERA 2 Access System (Arstasis, Redwood City, California, USA) was designed to create a low-angle arteriotomy in the femoral artery using the Seldinger technique. The shallow angle achieved by the AXERA Access Device allows for the percutaneous introduction of 5 Fr or 6 Fr vascular sheaths and a reduction in manual compression time necessary to obtain hemostasis at the end of the procedure, with the benefit of not having to implant a foreign body. Prior retrospective studies showed an excellent safety profile in nearly 450 patients undergoing diagnostic and interventional cardiac 24 and neuroendovascular 25 procedures. Considering its novel mechanism and avoidance of foreign body implantation, we began to use the device for femoral arterial access for neurovascular angiographic procedures. The alarmingly high rate of complications associated with the use of the AXERA 2 Access System resulted in the termination of our use of the device after 13 patients. Herein, we report our complications and review the extant literature pertaining to the use of the AXERA Access System.
Methods
In May 2013, the AXERA 2 Access System was utilized for femoral arteriotomy and introducer sheath placement in 13 patients undergoing cerebral arteriograms and interventions at the University of Pittsburgh Presbyterian Hospital. This study was approved by our Institutional Review Board and all subjects gave informed consent. All procedures performed were in accordance with our institutional guidelines. Arterial access was gained by two separate operators who had each completed over 1000 diagnostic cerebral arteriograms and neurointerventions. The operators had significant experience with other VCDs, including over 950
Mynx (AccessClosure, Mountain View, California, USA), Exoseal (Cordis Corporation, Bridgewater, NJ, USA), and Angio-Seal (St. Jude Medical, St. Paul, Minnesota, USA) deployments. In addition, prior to its use in patients, each operator underwent 2 weeks of training using the AXERA 2 Access System in a model; all access procedures were observed by a company representative to ensure that steps were properly followed. The common femoral artery was palpated just below the inguinal ligament and using fluoroscopy, a puncture site over the head of the femur was planned and confirmed. In the first two patients on whom the device was used for transfemoral access, as is typical at our institution, a micropuncture needle was used for initial access, followed by introduction of a nitinol Core wire and, using the Seldinger technique, a 5 Fr introducer (B-Braun, Melsungen, Germany). The AXERA 2 Access System was then used and a Pinnacle (Terumo Medical Corporation, Somerset, NJ, USA) 6 Fr vascular sheath was placed in the right common femoral artery. After experiencing our first complication, for the remaining 11 patients, arterial puncture was made with the standard 19-guage access needle provided with the AXERA 2 Access System and contrast was injected through the access needle to ensure that the arteriotomy was performed in a proper location as an added measure of safety. The AXERA 2 Access System was used according to the protocol provided by the manufacturers and as noted in previously published reports ( Figure 1 ). Once a 10cm Pinnacle 5 Fr or 6 Fr vascular sheath (Terumo, Somerset, New Jersey, USA) was placed into the femoral artery, all patients underwent a femoral arteriogram. This was again repeated at the end of the neuroendovascular procedure, after which, the sheath was removed and manual compression was held. Of note, our operators held manual compression for 8 min while the product instructions mention that manual compression for 5 min is required.
Results
The AXERA 2 Access System was utilized for femoral arteriotomy and introducer sheath placement in 13 patients undergoing cerebral arteriograms and interventions ( Table 1 ). The device was unsuccessful in achieving arterial access in two patients (15.4%); in both of these cases, we did not observe spontaneous blood return after the second arteriotomy with the micropuncture needle; as such, we converted to standard Seldinger technique and introduced the vascular sheath over the J-tip wire. There were a total of three complications associated with the use of the device. The minor complication involved a patient who developed a groin hematoma without requiring a blood transfusion. The major complications involved two patients who experienced common femoral artery occlusions from dissections, both of whom required an operative intervention.
Illustrative cases
Patient 2. A 63-year-old right-handed woman presented with a Hunt & Hess grade 2, Fisher grade 3 subarachnoid hemorrhage. The patient was taken to the angiography suite for a diagnostic cerebral arteriogram and endovascular treatment of a 6 mm basilar artery aneurysm under general anesthesia with neurophysiologic monitoring. The AXERA 2 Access System was used after the initial femoral arteriotomy was made with a micropuncture needle. After the diagnostic arteriogram revealed the aneurysm, the 10 cm Pinnacle 6 Fr introducer sheath was exchanged for an 80 cm 6F Cook shuttle guide sheath (Shuttle-SL; Cook Medical, Bloomington, IN, USA). Intravenous heparin was administered to maintain an ACT greater than 250, and the basilar apex aneurysm was sequentially coiled using an 072 Navien (Covidien, Irvine, CA, USA) intermediate catheter and an Eschelon-10 microcatheter (Covidien, Irvine, CA, USA). After the aneurysm was embolized, neurophysiological responses from the right leg were noted to be significantly decreased. A diagnostic arteriogram of the left internal carotid artery was unrevealing; subsequently, a right femoral arteriogram was performed revealing a common femoral artery Figure 1 . Transfemoral access utilizing the AXERA 2 Access System involves first puncturing the femoral artery with a 19-guage access needle and passing a 0.035'' J-tip Latchwire through the needle (a). After removing the access needle, the AXERA 2 Access Device is attached to the Latchwire and is introduced into the femoral artery. The metal footplate on the access device is deployed within the lumen of the femoral artery and the device is pulled back until the footplate is positioned against the endoluminal vessel wall (b). The AXERA 2 Access Device then creates a separate, low-angle arteriotomy a few millimeters distal to the initial puncture via a micropuncture needle integrated within the access device (c). Subsequently, a 0.018'' guidewire is introduced through the device into the arterial lumen, the footplate is released, and the access device is removed (d). Finally, using a dilator adaptor, a 5 Fr or 6 Fr vascular sheath is advanced into the femoral artery (e). Image courtesy of Arstasis http://www.arstasis.com The patient received a bolus of IV heparin and vascular surgery was consulted. The patient exhibited a weak Doppler signal of her anterior tibial artery and was emergently taken to the operating room. Upon opening the common femoral artery, the surgeons noted a large dissection plane extending distally into the superficial femoral artery (Figure 2 ). The dissection was repaired and a thrombectomy was performed of the right common femoral and superficial femoral arteries, followed by a patch angioplasty using a saphenous vein graft. Following the operation, the patient did not experience any other complications and was eventually discharged home.
Patient 13. A 46-year-old right-handed woman presented with an unremitting headache and seizures and was found to have a right frontal intraparenchymal hemorrhage. Her past neurosurgical history was significant for having undergone stereotactic radiosurgery 4 months prior for treatment of a previously unruptured right fronto-orbital arteriovenous malformation discovered on non-invasive imaging for workup of headaches. A diagnostic cerebral arteriogram was solicited to assess for potential venous outflow obstruction or interim development of a feeding artery aneurysm. After fluoroscopic confirmation of appropriate puncture location and no evidence of femoral artery calcifications or stenosis, the AXERA 2 Access System was used for introducer sheath placement (Figure 3(a, b) ). Prior to its removal, a diagnostic femoral arteriogram through the sheath revealed a femoral artery occlusion (Figure 3(c) ). Vascular surgery was consulted and the patient was taken to the operating room emergently. Under local heparinization, the patient's right common femoral artery was explored and a posterior wall dissection of the vessel with large amounts of clot was discovered. An endarterectomy was performed and a thromboembolectomy catheter was passed proximally and distally. Small clots were extracted and the artery was closed in primary fashion. Due to poor distal pulses, sequential cut-downs on the patient's popliteal, anterior tibial, and dorsalis pedis arteries were performed and flow was restored after clot retrieval with a thromboembolectomy catheter. Of note, the surgeons noted poor flow distal to the dorsalis pedis artery into the tarsal artery and elected to place the patient on an intravenous infusion of heparin postoperatively. On postoperative day 5, an arterial duplex study showed that the common femoral artery had re-occluded, necessitating a left-to-right femoral-femoral bypass using a Dacron graft. Following the second operation, the patient was again kept on intravenous heparin. She was eventually bridged to oral anticoagulation with warfarin upon discharge home. She returned to the hospital 13 days later in a comatose state with an INR of 1.7. A CT scan revealed a large right frontal intraparenchymal hemorrhage (Figure 4) . The patient progressed to brain death within 24 hours.
Discussion
Vascular access and post-procedural access-site management is predicated on patient safety and comfort, with a goal of achieving effective hemostasis in a short amount of time and rapid patient mobilization. Although approved by the Food and Drug Administration based on its safety and efficacy amongst a cohort of 117 patients and subsequent validation in cardiac and neurovascular literature, 24, 25 our experience with the second iteration of the AXERA Access System did not reveal a similarly benign safety profile. Amongst the 13 patients included herein, there were a total of three complications, two of which required an emergent endarterectomy procedure. The initial published results for the AXERA Access System were reported in a prospective, multicenter clinical investigation involving 346 patients who underwent cardiac catheterizations. 24 The AXERA device was successful in achieving femoral access in 97.1% of patients, with the time to hemostasis and time to ambulation found to be significantly shorter compared with historical controls on whom manual compression was performed for achievement of hemostasis, irrespective of whether an diagnostic or interventional procedure had been undertaken. The authors also reported a complication rate of 4%, with no major complications encountered. Moreover, the AXERA device had excellent results from the perspective of patient comfort: in the subset of patients who underwent transfemoral access for the first time, 83% reported that they were ''comfortable'' or ''very comfortable,'' and 74% experienced no pain associated with access. Amongst those individuals who had previous transfemoral procedures, 76% reported their comfort level as ''better'' or ''much better,'' and 70% experienced ''less'' or ''much less'' pain compared with their prior experience.
Fortes et al. 25 similarly demonstrated excellent results with the use of the AXERA device in 104 patients undergoing neuroendovascular procedures, 22% of whom underwent a neurointerventional procedure. In this series, the AXERA 2 device was successful in achieving arterial access in 102 of 104 cases. The median time to hemostasis was 4 min and only one complication -a minor groin hematoma -was reported. Taking into context the significant heterogeneity amongst the patient populations in the two studies, the efficacy and safety of the AXERA device noted by Turi et al. in the RECITAL trial 24 is especially noteworthy when considering: (1) patients who underwent an interventional cardiac catheterization comprised 28% of their cohort, (2) antiplatelet and/or anticoagulant agents were used in 71.7% of enrolled patients.
Another significant consideration is that the AXERA 2 Access System obviates the need for clips, sutures, sealant, or any such foreign implant to remain in the patient. As a result, this putatively reduces the risk of infection, vessel stenosis, or VCD-mediated limb ischemia. In turn, the lack of an implant left at the arteriotomy site allows for immediate, easy re-access to the vessel, a phenomenon that is oftentimes difficult over the short term in patients who undergo closure with other VCDs. Amongst patients with cerebrovascular pathology such as arteriovenous malformations, aneurysms, and intracranial vasospasm, this ability to easily and safely re-access previously catheterized femoral arteries over a short amount of time has added benefit.
The number and severity of complications with the AXERA 2 device in this small series is concerning. The retrograde dissection created by the footplate of the AXERA 2 device has the potential to create an intimal flap, which was the putative etiology behind the femoral artery occlusions observed in our patients. In the first case, the intimal flap was likely caused by the metal footplate being pulled up against the anterior wall of the vessel, while in the second case, the footplate may have scraped against the posterior vessel wall prior to the AXERA 2 device being pulled back, leading to the posterior wall dissection. After careful consideration, we could not determine any untoward events during placement or patient-specific risk factors that further contributed to complications. While inexperience with the device was one noteworthy factor, the incidence of complication development exceeds our own experience with other VCDs. In a recent publication, the Mynx device demonstrated a 92.0% efficacy in achieving closure, with 7/937 developing a complication requiring a surgical intervention. 26 This small series highlights a heretofore underreported serious complication rate of the AXERA 2 Access System. Additional studies are warranted to provide further insight into risk factors for device failure and complication development.
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